Filing Details
- Accession Number:
- 0001593968-24-000879
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-20 17:08:39
- Reporting Period:
- 2024-06-17
- Accepted Time:
- 2024-06-20 17:08:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1000694 | Novavax Inc | NVAX | Biological Products, (No Disgnostic Substances) (2836) | 222816046 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1977361 | Filip Dubovsky | 700 Quince Orchard Road Gaithersburg MD 20878 | President, R&D | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-06-17 | 1,404 | $6.97 | 68,017 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-06-17 | 12,500 | $6.09 | 80,517 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-06-17 | 12,500 | $14.46 | 68,017 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-06-17 | 1,404 | $14.54 | 66,613 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-06-17 | 1,404 | $6.97 | 1,404 | $6.97 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-06-17 | 12,500 | $6.09 | 12,500 | $6.09 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 46,324 | 2033-03-07 | No | 4 | M | Direct | |
| 37,500 | 2033-03-27 | No | 4 | M | Direct |
Footnotes
- Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Billionaire Hedge Funds
